Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, for the month of October 2021. The report was issued on October 5, 2021, to disclose a material corporate event regarding the Company's intellectual property portfolio.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the issuance of a notice of allowance by the Israeli Patent Office for a new patent application (number 255119). This patent covers AllocetraTM, the Company's immunotherapy product candidate.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the specific patent event. The document serves solely to incorporate the press release regarding the patent allowance by reference.
Investor Verification Checklist
- Verify the status and scope of patent application number 255119 with the Israeli Patent Office.
- Confirm the specific claims and expiration date of the patent covering AllocetraTM.
- Review the full text of the press release (Exhibit 99.1) for additional details on the immunotherapy product candidate.
- Check subsequent filings for any updates on the final grant of the patent.